Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
Saved in:
| Title: | Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities. |
|---|---|
| Authors: | Hack SP; Product Development (Oncology), Genentech, Inc., South San Francisco, CA, United States., Zhu AX; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, United States.; Jiahui International Cancer Center, Jiahui Health, Shanghai, China., Wang Y; Product Development (Oncology), Genentech, Inc., South San Francisco, CA, United States. |
| Source: | Frontiers in immunology [Front Immunol] 2020 Nov 05; Vol. 11, pp. 598877. Date of Electronic Publication: 2020 Nov 05 (Print Publication: 2020). |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
